Related Experiment Videos
Loss of heterozygosity at the human RAP1A/Krev-1 locus is a rare event in colorectal tumors
1Queensland Cancer Fund Research Unit, Joint Oncology Program, Queensland Institute of Medical Research, Herston, Australia.
Abstract:
Kirsten-ras-revertant-1 (Krev-1/Rap1A) is a recently identified tumor suppressor gene which induces flat revertants when introduced into a variety of ras-transformed cell lines in vitro. Since 47% of colorectal carcinomas have transforming mutations in ras protooncogenes, and since Krev-1 is expressed at high levels in normal colonic mucosa, we hypothesized that inactivation at the Krev-1 locus may be necessary for transformation of colonic cells. Loss of heterozygosity is a common method of inactivation of tumor suppressor genes in colorectal tumors. Therefore, we analyzed loss of heterozygosity in 52 patients with sporadic colorectal cancer. Because Krev-1 had no previously described polymorphisms, we first identified a BclI restriction fragment length polymorphism which showed 40% heterozygosity in 50 unrelated individuals. However, only one tumor from 18 informative patients showed allelic loss at the Krev-1 locus. This suggests that loss of heterozygosity is not a common mechanism of inactivation at the Krev-1 locus in colorectal cancer. However, the results do not exclude a role for Krev-1 in the etiology of this neoplasm because inactivation may occur by other mechanisms.
Insights
Kirsten-ras-revertant-1 (Krev-1) gene inactivation is not commonly caused by loss of heterozygosity in colorectal cancer. Other inactivation mechanisms may still play a role in tumor development.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Kirsten-ras-revertant-1 (Krev-1/Rap1A) is a tumor suppressor gene.
- Krev-1 induces flat revertants in ras-transformed cell lines.
- High Krev-1 expression is observed in normal colonic mucosa.
Purpose of the Study:
- To investigate if Krev-1 locus inactivation is necessary for colonic cell transformation.
- To analyze loss of heterozygosity at the Krev-1 locus in sporadic colorectal cancer.
Main Methods:
- Identified a BclI restriction fragment length polymorphism for Krev-1.
- Analyzed loss of heterozygosity in 52 sporadic colorectal cancer patients.
- Assessed polymorphism heterozygosity in 50 unrelated individuals.
Main Results:
- A BclI polymorphism with 40% heterozygosity was identified.
- Only one out of 18 informative tumors showed allelic loss at the Krev-1 locus.
- Loss of heterozygosity is not a common inactivation mechanism for Krev-1 in colorectal cancer.
Conclusions:
- Loss of heterozygosity is infrequent as a mechanism for Krev-1 inactivation in colorectal cancer.
- The study does not rule out other mechanisms of Krev-1 inactivation.
- Further research is needed to understand Krev-1's role in colorectal cancer etiology.